NDAINJECTIONINJECTABLE
Approved
Mar 2013
Lifecycle
LOE Approaching
Competitive Pressure
15/100
Clinical Trials
14
Data completeness
4/8 — Partial
LYMPHOSEEK KIT (tilmanocept) by R-Pharm US is (technetium tc 99m tilmanocept) is a radioactive diagnostic agent. First approved in 2013.
Drug data last refreshed 4h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LYMPHOSEEK KIT is a technetium Tc 99m-labeled diagnostic radiopharmaceutical that accumulates in lymphatic tissue by binding to mannose receptors (CD206) on macrophages and dendritic cells. It consists of a dextran backbone conjugated with mannose ligands and DTPA chelating agents for technetium labeling. The product is used for lymph node imaging and sentinel lymph node detection in oncology and other surgical applications.
LOE Approaching2.6 years to LOE
Product faces patent expiration in 2029 with limited linked job opportunities, indicating a small, stabilized team focused on maintenance and transition planning.
Mechanism of Action
(technetium Tc 99m tilmanocept) is a radioactive diagnostic agent. It accumulates in lymphatic tissue and selectively binds to mannose binding receptors (CD206) located on the surface of macrophages and dendritic cells. Technetium Tc 99m tilmanocept is a macromolecule consisting of multiple units…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (14)
Tc 99m Tilmanocept Imaging for Early Prediction of Anti-TNFα Therapy Response in Moderate to Severe Active RA
Started Mar 2022
169 enrolled
Rheumatoid Arthritis
Evaluating the Ability of 99mTc-Tilmanocept to Identify Clipped Nodes in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy and Sentinel Lymph Node Dissection
Started Mar 2022
14 enrolled
Breast Cancer
Comparison of Tc 99m Tilmanocept Imaging With IHC Analysis of CD206 Expression in Synovial Tissue of Subjects With RA
Started Sep 2021
20 enrolled
Rheumatoid Arthritis
Development of a Normative Database for Rheumatoid Arthritis (RA) Imaging With Tc99m Tilmanocept
Started May 2021
134 enrolled
Rheumatoid Arthritis
Dynamics and Tracer Distribution of Tilmanocept in Early Stage Breast Cancer
Started Nov 2020
0Breast CancerSentinel Lymph Node
Worked on LYMPHOSEEK KIT at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.